Nesiritide
Also referenced as: Natrecor
A recombinant B-type natriuretic peptide with historical heart-failure approval and subsequent withdrawal of approval.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Not FDA Approved
Natrecor was historically FDA-approved for a defined acute heart-failure indication; its approval was withdrawn effective June 15, 2020 and the product was discontinued.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A recombinant B-type natriuretic peptide with historical heart-failure approval and subsequent withdrawal of approval.
Natrecor was historically FDA-approved for a defined acute heart-failure indication; its approval was withdrawn effective June 15, 2020 and the product was discontinued.
Natrecor was approved, then discontinued; approval was withdrawn at the sponsor’s request in 2020. That history does not itself prove a safety-based withdrawal.
Why It's Being Studied
- Acute decompensated heart failure
- Natriuretic peptide signalling
Mechanism of Action
Natriuretic peptide receptor activation increases cyclic GMP, producing vascular and renal physiological effects.
Natriuretic peptide receptor activation increases cyclic GMP, producing vascular and renal physiological effects. Natrecor was approved, then discontinued; approval was withdrawn at the sponsor’s request in 2020. That history does not itself prove a safety-based withdrawal.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Acute decompensated heart failure
- Natriuretic peptide signalling
- Historical intravenous medicine
Evidence Summary
ASCEND-HF did not reduce death or readmission and did not meet its prespecified dyspnea-benefit criterion.
Higher tiers carry more weight. Filled tiers have evidence for Nesiritide; tap to read it.
- ASCEND-HF did not reduce death or readmission and did not meet its prespecified dyspnea-benefit criterion.
2 cited sources.
- Regulatory document1
- Randomised controlled trial1
Human clinical evidence
- ASCEND-HF did not reduce death or readmission and did not meet its prespecified dyspnea-benefit criterion.
Reported Adverse Events in Research
- Hypotension increased in clinical research and may be clinically significant.
Limitations of Current Evidence
- Natrecor was approved, then discontinued; approval was withdrawn at the sponsor’s request in 2020. That history does not itself prove a safety-based withdrawal.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Nesiritide | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Not FDA Approved | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Historical intravenous medicine | Oral approved medicine |
| Cited sources | 2 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Nesiritide — regulatory document
- Randomised controlled trial
ASCEND-HF randomized trial